EU Expands Label for AbbVie and Genmab's Tepkinly in Blood Cancer Treatment
The European Commission has approved an expanded label for Tepkinly, a bispecific antibody therapy developed by AbbVie (ABBV) and Genmab (GMAB), as a first-line treatment option for patients with follicular lymphoma. This approval broadens the therapeutic application of the drug in blood cancer management.
Topics: biotech cancer_therapy pharmaceuticals